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Abstract: Despite advances in stem cell biology, there are few effective techniques to promote the
osteogenic differentiation of human primary dedifferentiated fat (DFAT) cells. We attempted to
investigate whether epigallocatechin-3-gallate (EGCG), the main component of green tea catechin,
facilitates early osteogenic differentiation and mineralization on DFAT cells in vitro. DFAT cells
were treated with EGCG (1.25–10 µM) in osteogenic medium (OM) with or without 100 nM
dexamethasone (Dex) for 12 days (hereafter two osteogenic media were designated as OM(Dex)
and OM). Supplementation of 1.25 µM EGCG to both the media effectively increased the mRNA
expression of collagen 1 (COL1A1) and runt-related transcription factor 2 (RUNX2) and also
increased proliferation and mineralization. Compared to OM(Dex) with EGCG, OM with EGCG
induced earlier expression for COL1A1 and RUNX2 at day 1 and higher mineralization level at
day 12. OM(Dex) with 10 µM EGCG remarkably hampered the proliferation of the DFAT cells.
These results suggest that OM(without Dex) with EGCG might be a preferable medium to promote
proliferation and to induce osteoblast differentiation of DFAT cells. Our findings provide an insight
for the combinatory use of EGCG and DFAT cells for bone regeneration and stem cell-based therapy.
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1. Introduction
In the past decade, stem cell engineering has undergone significant advances. Various stem cells
have been extensively investigated for their potential for use in dental [1] and orthopedic surgery [2]
to treat conditions such as inflammatory diseases, trauma, and tumors. So far, induced pluripotent
stem cells and somatic stem cells, such as mesenchymal stem cells (MSCs) and adipocyte derived stem
cell (ADSCs), that exhibit multipotency and proliferative properties, have garnered great interest in
bone regenerative medicine.
Dedifferentiated fat (DFAT) cells isolated from adipose tissues are thought to be a
promising cell type for use in stem cell-based regenerative therapy [3]. Mature adipocytes begin to
dedifferentiate into elongated non-lipid-filled fibroblast-like cells when cultured in specific conditions
such as by using ceiling culture technique [4] and hydrogels [5] in vitro. The cells differentiate into
multiple cell lineages, including osteoblasts [3,6–15], chondrocytes [3,14,16], adipocytes [3,15,17],
myocytes [14,15,18–20], and endothelial cells [21]. Expression markers and proliferative capacity
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of DFAT cells are analogous to those of MSCs and ADSCs, but are more homogenous [3,22]. The
expression of embryonic stem cell markers in DFAT cells was also similar to that in ADSCs [23].
DFAT cells have also been known to be able to differentiate into osteoblasts much earlier than MSCs
or ADSCs [8,24].
Epigallocatechin-3-gallate (EGCG), which is the most abundant polyphenol in green tea catechin,
has attracted intense interest as a health-promoting agent owing to its anti-inflammatory, anticancer,
antioxidant, and anti-atherogenic properties [25]. This polyphenol controls multiple signaling
pathways, including the extracellular signal-regulated kinase (ERK) [26], c-Jun N-terminal kinase
(JNK) [27,28], mitogen-activated protein/ERK kinase 1/2 [27], signal tranducer and activator of
transcription 3 (STAT3) [27,29], and phosphoinositide-3kinase/Akt pathways [26,27,30,31], which are
responsible for a variety of cellular responses, including proliferation [27,32], differentiation [31–33],
cytokine production [28,30], and survival [26]. Therefore, the potential for the therapeutic use of
EGCG for various diseases such as carcinomas [30], metabolic syndrome [34], oral diseases [35],
cardiovascular diseases [36], and bone diseases [37–39] has been extensively studied.
In bones, EGCG is known to modulate bone metabolism [40], bone formation [37,39],
and bone resorption [41] even in vivo. In in vitro studies, EGCG has been known to hinder
osteoclastogenesis [41], while it induces osteoblast differentiation in mesenchymal stem
cells [32,42,43] and activates bone-like cells [33,44]. However, there is no study regarding the effect
of EGCG on osteoblastic differentiation of DFAT cells. Considering the easier availability of fat tissue
in comparison with that of the bone marrow, osteogenically differentiated DFAT cells are a potential
and attractive cell source for developing bone regeneration therapies and drug discovery.
Therefore, in this study, we investigated whether EGCG promotes the osteoblast differentiation
of primary human DFAT cells using two osteogenic media: (1) OM: osteogenic medium without
dexamethasone (Dex); (2) OM(Dex): OM with Dex. (The detailed compositions of the two media
have been provided in Table 1). Hereafter in this paper, the media formed by supplementing
EGCG in OM or OM(Dex) are designated as OM + EGCG(N) or OM(Dex) + EGCG(N), respectively,
where N = concentration of EGCG (µM). To determine the detailed mechanisms underlying the
osteogenic capability of EGCG in two media, we used inhibitors of four signal transduction pathways:
p38-mitogen-activated protein kinase (p38-MAPK), Akt, ERK1/2, and JNK pathways.
Table 1. Medium compositions.
Media Abbreviation Composition Dex
Control medium Control
Basal Dulbecco’s modified eagle
medium with 10% FBS and
1% antibiotics
´
Osteogenic medium 1 OM Control medium with 50 µM AA2Pand 10 mM bGP ´
Osteogenic medium 1
with EGCG OM + EGCG(N)
OM with
1.25–10 µM EGCG ´
Osteogenic medium 2 OM(Dex)
Control medium with 50 µM AA2P,
10 mM bGP and
100 nM Dex
+
Osteogenic medium 2
with EGCG OM(Dex) + EGCG(N)
OM(Dex) with
1.25–10 µM EGCG +
N in EGCG(N): concentration of EGCG (µM); EGCG = epigallocatechin-3-gallate; Dex = dexamethasone;
AA2P = ascorbic acid 2-phosphate; FBS = fetal bovine serum; bGP = β-glycerophosphate.
2. Results
2.1. Effect of Epigallocatechin-3-Gallate (EGCG) on the Proliferation of Dedifferentiated Fat (DFAT) Cells
The DFAT cells were cultured in cell seeding condition 1. At day 12, the supplementation
of 1.25 µM EGCG most effectively enhanced the proliferation of the cells (Figure 1). Meanwhile,
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OM(Dex) + EGCG(10.0) resulted in remarkably lower proliferation compared to the control and
OM(Dex) treatments. This suggested that excess EGCG in conjunction with Dex is likely to hinder
the proliferation of DFAT cells.
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Figure 1. Results of the cell proliferation assay. OM: osteogenic medium without Dex; OM(Dex):  
OM with 100 nM Dex. Control: control medium. Cells were seeded in condition 1 and were 
subjected to EGCG in OM or OM(Dex). N in EGCG(N): concentration of EGCG (μM). * p < 0.05, ** p < 
0.01 (Analysis of variance (ANOVA) with a Tukey–Kramer test). The bar graph shows the mean with 
standard deviation (n = 4). 
2.2. mRNA Expression Levels of Osteogenic Markers and Alkaline Phosphatase Assay 
Tables 2 and 3 show the mRNA expression levels of osteogenic markers associated with  
EGCG-induced osteoblast differentiation of the DFAT cells at days 1 and 6. EGCG(1.25) administration 
resulted in higher expression of the early osteogenic markers collagen type 1 α 1 (COL1A1) and 
Runt-related transcription factor 2 (RUNX2) compared with the expression levels observed with  
OM and OM(Dex) treatment at day 1. The expression level of OM + EGCG(1.25) was approximately 
4-fold higher than that treated with OM(Dex) + EGCG(1.25). At day 6, the expression levels of 
RUNX2, Osterix (OSX), and distal-less homeobox 5 (DLX5) were upregulated by the treatment with 
or without EGCG in two different osteogenic media. Earlier expression of Osteocalcin (OCN) was 
observed in the cells treated with EGCG in OM (Table 3). 
Figure 2 shows the alkaline phosphatase (ALP) staining and the corresponding quantitative 
data for ALP expression of the cells treated with or without EGCG in two different osteogenic 
media. Strong ALP staining was observed in the cells treated with EGCG(1.25) in both OM and 
OM(Dex) at day 6. The cells treated with OM(Dex) + EGCG(1.25) showed stronger ALP staining than 
those cultured with OM + EGCG(1.25). 
Table 2. mRNA expression levels of osteogenic markers in dedifferentiated fat (DFAT) cells treated 
with media on day 1. 
mRNA COL1A1 RUNX2 OSX DLX5 
Methods Media Units 
qPCR Fold 
(vs. Control) 
Digital PCR 
Copy/μL 
Digital PCR 
Copy/μL 
Digital PCR  
Copy/μL 
Control 1.08 ± 0.46 c,d 32.99 ± 4.27 c 15.42 ± 1.38 d 22.78 ± 1.85 b,c 
OM 3.32 ± 1.20 223.59 ± 15.17 13.33 ± 0.81 32.21 ± 2.55 
OM + EGCG(1.25) 31.10 ± 7.93 c 276.72 ± 3.44 c 71.11 ± 20.84 c 26.43 ± 1.05 a 
OM + EGCG(10.0) 8.16 ± 5.65 19.33 ± 0.84 21.00 ± 3.39 27.05 ± 1.27 a 
OM(Dex) 0.72 ± 0.45 36.11 ± 2.29 9.81 ± 0.01 26.51 ± 0.17 
OM(Dex) + EGCG(1.25) 7.07 ± 1.29 d 60.93 ± 4.28 d 12.32 ± 0.07 d 25.58 ± 0.66 
OM(Dex) + EGCG(10.0) 1.97 ± 0.72 17.38 ± 0.57 d 18.66 ± 0.77 d 26.16 ± 1.09 
OM: osteogenic medium without Dex; OM(Dex): OM with 100 nM Dex. Control: control medium. 
Cells were treated with Condition 2. N in EGCG(N): concentration of EGCG (μM). Values: mean 
with standard deviation (n = 4). a,b: p < 0.05; c,d: p < 0.01 (ANOVA with a Tukey–Kramer test). a,c: vs. 
OM; b,d: vs. OM(Dex). COL1A1: collagen type 1 α 1; RUNX2: runt-related transcription factor 2; OSX: 
osterix; DLX5: distal-less homeobox 5. 
Figure 1. Results of the cell proliferation assay. OM: osteogenic medium without Dex; OM(Dex): OM
ith 100 nM Dex. Contr l: c ntrol mediu . Cells wer seeded in condition 1 and were subjected
to EGCG in OM or OM(Dex). N in EGCG(N): concentration of EGCG (µM). * p < 0.05, ** p < 0.01
(Analysis of variance (ANOVA) with a Tukey–Kramer test). The bar graph shows the mean with
standard deviation (n = 4).
2.2. mRNA Expression Levels of Osteogenic Markers and Alkaline Phosphatase Assay
Tables 2 and 3 show the mRNA expression levels of osteogenic markers associated with
EGCG-induced osteoblast differentiation of the DFAT cells at days 1 and 6. EGCG(1.25)
administration resulted in higher expression of the early osteogenic markers collagen type 1 α 1
(COL1A1) and Runt-related transcription factor 2 (RUNX2) compared with the expression levels
observed with OM and OM(Dex) treatment at day 1. The expression level of OM + EGCG(1.25)
was approximately 4-fold higher than that treated with OM(Dex) + EGCG(1. ). At day 6, the
expression levels of RUNX2, Osterix (OSX), and distal-less homeobox 5 (DLX5) were upregu ated
by the tr atment with or without EGCG in two different osteogenic medi . Earlier xpression of
Osteocalcin (OCN) as observed in the cells treated with EGCG in OM (Table 3).
Figure 2 shows the alkaline phosphatase (ALP) staining and the corresponding quantitative data
for ALP expression of the cells treated with or without EGCG in two different osteogenic media.
Strong ALP staining was observed in the cells treated with EGCG(1.25) in both OM and OM(Dex)
at day 6. The cells treated with OM(Dex) + EGCG(1.25) showed stronger ALP staining than those
cultured with OM + EGCG(1.25).
Table 2. mRNA expression levels of osteogenic markers in dedifferentiated fat (DFAT) cells treated
with media on day 1.
mRNA COL1A1 RUNX2 OSX DLX5
Media Methods Units qPCR Fold (vs. Control) Digital PCR Copy/µL Digital PCR Copy/µL Digital PCR Copy/µL
Control 1.08˘ 0.46 c,d 32.99˘ 4.27 c 15.42˘ 1.38 d 22.78˘ 1.85 b,c
OM 3.32˘ 1.20 223.59˘ 15.17 13.33˘ 0.81 32.21˘ 2.55
OM + EGCG(1.25) 31.10˘ 7.93 c 276.72˘ 3.44 c 71.11˘ 20.84 c 26.43˘ 1.05 a
OM + EGCG(10.0) 8.16˘ 5.65 19.33˘ 0.84 21.00˘ 3.39 27.05˘ 1.27 a
OM(Dex) 0.72˘ 0.45 36.11˘ 2.29 9.81˘ 0.01 26.51˘ 0.17
OM(Dex) + EGCG(1.25) 7.07˘ 1.29 d 60.93˘ 4.28 d 12.32˘ 0.07 d 25.58˘ 0.66
OM(Dex) + EGCG(10.0) 1.97˘ 0.72 17.38˘ 0.57 d 18.66˘ 0.77 d 26.16˘ 1.09
OM: osteogenic medium without Dex; OM(Dex): OM with 100 nM Dex. Control: control medium. Cells were
treated with Condition 2. N in EGCG(N): concentration of EGCG (µM). Values: mean with standard deviation
(n = 4). a,b: p < 0.05; c,d: p < 0.01 (ANOVA with a Tukey–Kramer test). a,c: vs. OM; b,d: vs. OM(Dex). COL1A1:
collagen type 1 α 1; RUNX2: runt-related transcription factor 2; OSX: osterix; DLX5: distal-less homeobox 5.
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Table 3. mRNA expression levels of osteogenic markers in DFAT cells treated with media on day 6.
mRNA COL1A1 RUNX2 OSX DLX5 OCN
Media Units Fold(vs. Control)
Fold
(vs. Control)
Fold
(vs. Control)
Fold
(vs. Control)
Fold
(vs. Control)
Control 1.02˘ 0.23 c,d 1.17˘ 0.71 b,c 1.01˘ 0.12 c,d 1.02˘ 0.21 c,d 1.16˘ 0.59 d
OM 0.15˘ 0.02 5.00˘ 0.79 20.68˘ 6.58 2.54˘ 0.14 31.74˘ 12.28
OM + EGCG(1.25) 0.27˘ 0.08 4.56˘ 0.72 36.01˘ 3.10 c 3.41˘ 0.15 c 140.46˘ 65.44 c
OM + EGCG(10.0) 0.20˘ 0.03 3.71˘ 1.35 52.57˘ 9.29 c 2.38˘ 0.13 71.83˘ 5.45
OM(Dex) 0.52˘ 0.08 2.79˘ 0.58 16.94˘ 0.71 1.93˘ 0.20 0.43˘ 0.03
OM(Dex) + EGCG(1.25) 0.40˘ 0.04 2.38˘ 0.40 29.62˘ 4.60 d 2.39˘ 0.44 1.03˘ 0.10 d
OM(Dex) + EGCG(10.0) 0.18˘ 0.02 d 3.04˘ 0.89 25.24˘ 0.18 d 2.17˘ 0.04 0.88˘ 0.15 d
OM: osteogenic medium without Dex; OM(Dex): OM with 100 nM Dex. Control: control medium. mRNA
expression was evaluated using qPCR. Cells were treated with Condition 2. N in EGCG(N): concentration
of EGCG (µM). Values: mean with standard deviation (n = 4). b: p < 0.05; c,d: p < 0.01 (ANOVA with a
Tukey–Kramer test). c: vs. OM; b,d: vs. OM(Dex). COL1A1: collagen type 1 α 1; RUNX2: runt-related
transcription factor 2; OSX: osterix; DLX5: distal-less homeobox 5; OCN: osteocalcin.
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Figure 2. Alkaline Phosphatase (ALP) staining and the corresponding quantitative data for ALP 
expression of DFAT cells treated with or without EGCG in two different osteogenic media.  
OM: osteogenic medium without Dex; OM(Dex): OM with 100 nM Dex. Control: control medium. 
Cells were treated under condition 2. N in EGCG(N): concentration of EGCG (μM). ** p < 0.01 
(ANOVA with a Tukey–Kramer test) indicates a statistically significant difference against OM or 
OM(Dex). The bar graph shows the mean with standard deviation (n = 4). 
2.3. Mineralization 
Mineralization indicated by the intensity of alizarin red staining gradually increased in the cells 
treated with OM or OM(Dex) with or without EGCG (Figure 3). OM(Dex) without EGCG resulted in 
higher mineralization than that observed with OM without EGCG. When EGCG was added in two 
osteogenic media, EGCG(1.25) resulted in significantly higher alizarin red staining compared with 
that observed with OM or OM(Dex) alone. OM + EGCG(1.25) treatment yielded stronger alizarin 
red staining than that observed with OM(Dex) + EGCG(1.25), suggesting that supplementation of 
Dex attenuated the mineralization induced in DFAT cells under the conditions of EGCG 
stimulation. 
Figure 2. Alkaline Phosphatase (ALP) staining and the corresponding quantitative data for ALP
expression of DFAT cells treated with or without EGCG in two different osteogenic media. OM:
osteogenic medium without Dex; OM(Dex): OM with 100 nM Dex. Control: control medium. Cells
were treated under condition 2. N in EGCG(N): concentration of EGCG (µM). ** p < 0.01 (ANOVA
with a Tukey–Kramer test) indicates a statistically significant difference against OM or OM(Dex). The
bar graph shows the mean with standard deviation (n = 4).
2.3. Mineralization
Mineralization indicated by the intensity of alizarin red staining gradually increased in the cells
treated with OM or OM(Dex) with or without EGCG (Figure 3). OM(Dex) without EGCG resulted in
higher mineralization than that observed with OM without EGCG. When EGCG was added in two
osteogenic media, EGCG(1.25) resulted in significantly higher alizarin red staining compared with
that observed with OM or OM(Dex) alone. OM + EGCG(1.25) treatment yielded stronger alizarin red
staining than that observed with OM(Dex) + EGCG(1.25), suggesting that supplementation of Dex
attenuated the mineralization induced in DFAT cells under the conditions of EGCG stimulation.
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Figure 3. Alizarin red staining of DFAT cells treated with or without EGCG in two different 
osteogenic media and the corresponding quantitative data. OM: osteogenic medium without Dex; 
OM(Dex): OM with 100 nM Dex. The cells were treated under condition 2. N in EGCG(N): 
concentration of EGCG (μM). * p < 0.05, ** p < 0.01 (ANOVA with a Tukey-Kramer test) indicates a 
statistically significant difference against OM or OM(Dex). The bar graph shows the mean with 
standard deviation (n = 4). 
2.4. Inhibitory Assay to Evaluate EGCG-Induced Osteoblast Differentiation of DFAT Cells 
We further attempted to clarify the mechanisms underlying the osteogenic capability of OM or 
OM(Dex) with EGCG by using alizarin red staining and inhibitors of four signal transduction 
pathways: PD98059 for ERK1/2, API-2 for Akt, SB203580 for p38-MAPK, and SP600125 for JNK 
(Figure 4). Administration of the Akt inhibitor inhibited the mineralization of the cells treated with 
OM + EGCG(1.25) and OM(Dex) + EGCG(1.25) to a similar level. In contrast, there were obvious 
differences between the effects of the inhibitors of the ERK1/2, JNK, and p38-MAPK pathways.  
In particular, the effect of the p38-MAPK inhibitor on the mineralization in the cells treated with  
OM + EGCG(1.25) was opposite to that observed in the cells treated with OM(Dex) + EGCG(1.25). 
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2.4. Inhibitory Assay to Evaluate EGCG-Induced Osteoblast Differentiation of DFAT Cells
We further attempted to clarify the mechanisms underlying the osteogenic capability of OM
or OM(Dex) with EGCG by using alizarin red staining and inhibitors of four signal transduction
pathways: PD98059 for ERK1/2, API-2 for Akt, SB203580 for p38-MAPK, and SP600125 for JNK
(Figure 4). Administration of the Akt inhibitor inhibited the mineralization of the cells treated with
OM + EGCG(1.25) and OM(Dex) + EGCG(1.25) to a similar level. In contrast, there were obvious
differences between the effects of the inhibitors of the ERK1/2, JNK, and p38-MAPK pathways.
In particular, the effect of the p38-MAPK inhibitor on the mineralization in the cells treated with
OM + EGCG(1.25) was opposite to that observed in the cells treated with OM(Dex) + EGCG(1.25).
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Figure 4. Effect of inhibitors of the extracellular signal-regulated kinase (ERK) 1/2, Akt, c-Jun 
N-terminal kinase (JNK) and p38-mitogen-activated protein kinase (MAPK) signaling pathways on  
EGCG-induced mineralization. Cells were seeded under condition 2. OM: osteogenic medium 
without Dex. OM(Dex): OM with 100 nM Dex. The cells were treated with or without inhibitors in 
OM + EGCG(1.25) or OM(Dex) + EGCG(1.25) for 12 days. N in EGCG(N): concentration of EGCG 
(μM). The concentrations of the inhibitors were designated as + and ++: 2.5 and 25 μM for the ERK1/2 
inhibitor PD98059; 1 and 10 μM for the JNK inhibitor SP600125; and 1 and 10 μM for the p38-MAPK 
inhibitor SB203580 (the Akt inhibitor API-2 was used at 1 μM, designated as +). The alizarin red 
staining levels of the samples were normalized against those of the cells treated with OM + 
EGCG(1.25) or OM(Dex) + EGCG(1.25) without inhibitors. * p < 0.05, ** p < 0.01 (ANOVA with a 
Dunnett’s test and Student’s t-test). The bar graph shows the mean with standard deviation (n = 4). 
3. Discussion 
In the present study, we showed that the supplementation of EGCG in OM and OM(Dex) 
resulted in significantly higher proliferation and mineralization, and earlier osteoblast 
differentiation for DFAT cells than that observed with conventional OM and OM(Dex) alone. OM + 
EGCG induced earlier osteogenic differentiation and higher mineralization level than that with 
OM(Dex) + EGCG. Using the inhibitors for four signaling pathways, we found differences in the 
effect of the ERK1/2, JNK and p38-MAPK pathways on the EGCG-induced mineralization between 
the cells treated with OM + EGCG and OM(Dex) + EGCG. This result suggested that the 
supplementation of Dex in OM markedly altered the signaling pathways of DFAT cells, thereby 
attenuating the osteogenic capability of EGCG. 
Although this is the first report that addresses the guiding of cell fate and proliferation of 
DFAT cells by EGCG, its effects on MSCs and osteoblasts have been previously investigated at the 
concentration range of 1–100 μM [40]. In previous studies, the concentration superior to induce  
the mineralization of human MSCs [32] and human osteoblast-like cells [33] was found to be 5 μm, 
and that for mouse MSCs was found to be 10 μM [42]. Jin et al. reported that 10 μM EGCG 
attenuated cell growth, but that the level of cell growth was still higher than that of cells treated 
with control media [32]. Consistent with this result, our results showed that EGCG administration 
induced the mineralization and enhanced the proliferation of DFAT cells at similar concentration 
ranges as those used in previous studies. However, the strongest induction of mineralization was 
observed with 1.25 μM EGCG, which is lower than concentration used in previous studies. The 
proliferation of DFAT cells cultured in OM(Dex) + EGCG(10.0) was remarkably lower than that of 
cells cultured in the control medium. These results suggest that the DFAT cells responded to EGCG 
as well as MSCs and osteoblasts, while their susceptibility to the effect of EGCG might be higher 
than that of MSCs and osteoblasts. 
The osteoblast maturation process is known to proceed in the following four steps: lineage 
commitment, proliferation, maturation, and mineralization [45]. Collagen 1, Runx2, Osterix, and  
Dlx-5 are mainly expressed in the proliferation or maturation stages [45]. ALP is thought to be  
a defined marker for osteoblastogenesis [46,47] and is a key regulator that promotes the 
Figure 4. Effect of inhibitors of the extracellular signal-regulated kinase (ERK) 1/2, Akt, c-Jun
N-terminal kinase (JNK) and p38-mitogen-activated protein kinase (MAPK) signaling pathways on
EGCG-induced mineralization. Cells were seeded under condition 2. OM: osteogenic medium
without Dex. OM(Dex): OM with 100 nM Dex. The cells were treated with or without inhibitors in
OM + EGCG(1.25) or OM(Dex) + EGCG(1.25) for 12 days. N in EGCG(N): concentration of EGCG
(µ ). The concentrations of the inhibitors were designated as + and ++: 2.5 and 25 µM for the
ERK1/2 inhibitor PD98059; 1 and 10 µM for the JNK inhibitor SP600125; and 1 and 10 µM for the
p38-MAPK inhibitor SB203580 (the Akt inhibitor API-2 was used at 1 µM, designated as +). The
alizarin red staining levels of the samples were normalized against those of the cells treated with OM
+ EGCG(1.25) or OM(Dex) + EGCG(1.25) without inhibitors. * p < 0.05, ** p < 0.01 (A OV ith a
nnett’s test an St ent’s t-test). he bar graph sho s the ean ith stan ar eviation (n 4).
3. Discussion
In the present study, we showed that the supplementation of EGCG in OM and OM(Dex)
resulted in significantly higher proliferation and mineralization, and earlier osteoblast differentiation
for DFAT cells than that observed with conventional OM and OM(Dex) alone. OM + EGCG induced
earlier osteogenic differentiation and higher mineralization level than that with OM(Dex) + EGCG.
Using the inhibitors for four signaling pathways, we found differences in the effect of the ERK1/2,
JNK and p38-MAPK pathways on the EGCG-induced mineralization between the cells treated with
OM + EGCG and OM(Dex) + EGCG. This result suggested that the supplementation of Dex in OM
markedly altered the signaling pathways of DFAT cells, thereby attenuating the osteogenic capability
of EGCG.
Although this is the first report that addresses the guiding of cell fate and proliferation of
DFAT cells by EGCG, its effects on MSCs and osteoblasts have been previously investigated at the
concentration range of 1–100 µM [40]. In previous studies, the concentration superior to induce the
mineralization of human MSCs [32] and human osteoblast-like cells [33] was found to be 5 µm, and
that for mouse MSCs was found to be 10 µM [42]. Jin et al. reported that 10 µM EGCG attenuated
cell growth, but that the level of cell growth was still higher than that of cells treated with control
media [32]. Consistent with this result, our results showed that EGCG administration induced the
mineralization and enhanced the proliferation of DFAT cells at similar concentration ranges as those
used in previous studies. However, the strongest induction of mineralization was observed with
1.25 µM EGCG, which is lower than concentration used in previous studies. The proliferation of
DFAT cells cultured in OM(Dex) + EGCG(10.0) was remarkably lower than that of cells cultured in
the control medium. These results suggest that the DFAT cells responded to EGCG as well as MSCs
and osteoblasts, while their susceptibility to the effect of EGCG might be higher than that of MSCs
and osteoblasts.
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The osteoblast maturation process is known to proceed in the following four steps: lineage
commitment, proliferation, maturation, and mineralization [45]. Collagen 1, Runx2, Osterix, and
Dlx-5 are mainly expressed in the proliferation or maturation stages [45]. ALP is thought to be a
defined marker for osteoblastogenesis [46,47] and is a key regulator that promotes the mineralization
of the bone matrix [46,48]. Nevertheless, our results show that the supplementation of Dex into OM
+ EGCG enhanced the ALP staining level of the cells, but decreased the alizarin red staining level
(Figures 2 and 3). This discrepancy might be explained by the possible synergistic effect of EGCG and
Dex on the activation of STAT3 signaling. EGCG administration modulates collagen production and
proliferation in fibroblasts through STAT3 signaling [27]. In addition, Mikami et al. have reported
that Dex administration markedly enhances ALP production via activation of STAT3 signaling [47].
Further, Peruzzi et al. have reported the possibility that this pathway impairs osteoblast maturation
in vivo and in vitro. COL1A1 and Runx2 expression is also known to be increased by STAT3 siRNA
treatment [49]. Consistent with the results of these studies, our results show that simultaneous
administration of EGCG and Dex in OM remarkably increased ALP staining (Figure 2) and decreased
the mRNA expression of COL1A1 and RUNX2 as well as mineralization. Although the effect of
STAT3 pathways on osteoblastogenesis is still a controversial topic [47,49–51], the activation of STAT3
signaling might be partially associated with the attenuated mineralization observed in the DFAT cells
treated with a combination of Dex and EGCG in OM in our study.
Cocktails of Dex, AA2P (or ascorbic acid), and bGP have been widely used to supplement
media to promote the osteogenic differentiation of multipotent stem cells [52] such as ADSCs [53,54],
MSCs [55–57], and DFAT cells [3,24]. Supplementation of Dex in the medium is an effective
technique to induce the osteoblast differentiation of human MSCs [52,55], wherein Dex acts via
the augmentation of the transcripts of the LIM-domain protein with 4.5 LIM domains [52,58]. In
agreement with these results, our results showed that stronger mineralization occurred in human
DFAT cells treated with OM(Dex) than that observed with OM (Figure 3). However, the results
were reversed by the addition of EGCG in two osteogenic media. Using inhibitors of four signal
transduction pathways, we found apparent differences in the effects of the ERK, JNK, and p38-MAPK
pathways on mineralization between the treatments with OM + EGCG and OM(Dex) + EGCG
(Figure 4). The MAPK cascade (ERK, JNK, and P38-MAPK) and Akt signaling modulate processes
that determine cell fate, such as proliferation, differentiation, and apoptosis [59,60]. Similar MAPK
kinetic profiles often yield opposite cellular fates according to the type of cell and signal intensity.
Thus, the network of these pathways has been vigorously investigated [59]. Additionally, it is
recognized that the crosstalk between signaling pathways regulates epigenetic mechanisms [61].
Unfortunately, we could not determine the detailed mechanism underlying the osteogenic capability
of EGCG in DFAT cells. The optimal harmony between the signaling pathways and epigenetic
mechanisms might be associated with the osteogenic capability of OM + EGCG.
A combination of stem cells, scaffold, and osteoinductive reagents is considered as a prospective
approach for bone disease repair [62]. Compared with the wide use of growth factors in bone
regeneration therapy [62], the application of polyphenols is still limited despite its various advantages
such as cost-effectiveness. More recently, we reported that EGCG-conjugated gelatin composites
strategically and locally released polyphenol in a critical-sized defect in mouse calvaria, thereby
inducing bone formation at a low dose of EGCG [39]. Previous studies have demonstrated the
effectiveness of the use of DFAT cells in bone therapies [12,63]. In view of the high accessibility
of adipose tissues, preparing a sufficient quantity of DFAT cells would be more feasible than
obtaining bone marrow-derived MSCs. With this background, the implantation of DFAT cells in
combination with EGCG-conjugated scaffolds might be a prospective strategy to facilitate bone
formation in orthopedic and maxillofacial regions. In the present study, we proposed an effective
technique to promote early osteoblastic differentiation in DFAT cells using EGCG. However,
further detailed research is essential to verify the in vitro and in vivo fate of the cells produced
by this technique. In particular, it would be valuable to evaluate the gene expression pattern of
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DFAT-derived osteogenic differentiation in order to demonstrate the difference between these cells
and intact osteoblasts or other osteoblastic cells. In addition, there is still no information about the
main receptor of EGCG that positively and functionally promotes the osteoblast differentiation of
DFAT cells. Thus, identification of such molecules is an essential step toward developing safe and
reliable bone regeneration therapies using DFAT cells and EGCG.
4. Experimental Section
4.1. Chemicals
EGCG was purchased from BioVerde Inc. (Kyoto, Japan). The inhibitors of the four signaling
pathways, ERK1/2 (PD98059), Akt (API-2), JNK (SP600125), and p38-MAPK (SB203580) were
purchased from Sigma (Sigma-Aldrich Co. LLC, St. Louis, MO, USA).
4.2. Preparation and Maintenance of Primary Human DFAT Cells
DFAT cells were prepared from the subcutaneous adipose tissue of a healthy 63-year-old male
patient, who underwent oral and maxillofacial surgery. This study adheres to the declaration of
Helsinki, and the whole protocol was approved by the local ethics committee of Amagasaki Chuo
Hospital and Osaka Dental University (approval number: 110839; 31 March 2015). Ceiling culture
method was used for isolating the DFAT cells from adipose tissue as reported previously [16,24].
In brief, minced adipose tissues were filtered using a nylon mesh to eliminate undesirable
components such as vascular cells, and connective tissues. Obtained mature adipocytes containing
lipid droplets were then added into an overturned culture flask. The floating adipocytes adhered to
the ceiling of the flask. One week later, the flask was reversed to eliminate the mature adipocytes.
Thereafter, we could observe some residual mature adipocytes in the flask, and these cells were
gradually removed after several passages. DFAT cells resembling fibroblastic cells occupied the
bottom of the flask (Supplementary Figure S1). The DFAT cells were cultured in Dulbecco’s modified
essential medium supplemented with 10% fetal bovine serum and 1% antibiotics in a 5% CO2
incubator at 37 ˝C. DFAT cells at passages 6–8 were used for each assay. Images of cell morphology
were obtained using an optical microscope (IX70, Olympus, Tokyo, Japan).
4.3. Cell Seeding Conditions for the Proliferation Assay and Osteogenic Differentiation
To investigate the proliferation and osteoblast differentiation of the DFAT cells, the cells
were seeded with the control medium under two conditions: 1 ˆ 103/well for condition 1 and
3.5 ˆ 104/well for condition 2 in 48 well plate. In condition 1, one day after the cells were seeded,
they were treated with the five different media listed in Table 1. In condition 2, approximately one
day after the cells were seeded, they were treated with basal medium for 17 h and then with the
five different media listed in Table 1. The two conditions were applied in order to highlight the
proliferation process (condition 1) and to accelerate cell differentiation (condition 2).
4.4. Cell Proliferation Assay
DFAT cells were seeded under condition 1. At the prescribed dates, cell proliferation was
examined using the cell counting kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the
manufacturer’s instruction manual.
4.5. RNA Isolation, Quantitative Real Time-PCR (qPCR), and Digital PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA). Reverse
transcription was performed with 200 ng RNA using the Transcriptor Universal cDNA Master (Roche
Diagnostics, Mannheim, Germany). mRNA levels of osteogenic markers were partially analyzed by
qPCR using a TaqMan Gene Expression Assay (ThermoFisher Scientific Inc., Waltham, MA, USA)
on a Step One Plus PCR system (ThermoFisher Scientific Inc.). The glyceraldehyde-3-phosphate
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dehydrogenase (GAPDH) gene was used as an internal standard (Human GAPDH endogenous
control; ThermoFisher Scientific Inc.). The PCR cycling conditions were as follows: 2 min at 50 ˝C,
20 s at 95 ˝C, 40 cycles of 1 s at 95 ˝C, 20 s at 60 ˝C. The signals were normalized to the GAPDH
signal. mRNA expression levels were calculated using the comparative CT method. RUNX2,
OSX, and DLX5 expression at day 1 was evaluated using the QuantStudio 3D digital PCR system
(ThermoFisher Scientific Inc.) with the QuantStudio 3D Master Mix (ThermoFisher Scientific Inc.)
and Gene expression assay (ThermoFisher Scientific Inc.). The cycling conditions were as follows:
10 min at 96 ˝C, 39 cycles of 2 min at 60 ˝C, 30 s at 98 ˝C, and 2 min at 60 ˝C. The assay IDs of TaqMan
Gene Expression Assay and the accession numbers used for the qPCR and digital PCR systems are
as follows: COL1A1, Hs00164004_m1, BC036531.2; RUNX2, Hs01047973_m1, NM_001015051.3;
DLX5, Hs00193291_m1, NM_005221.5; SP7(OSX), Hs01866874_s1, NM_152860.1; OCN,
Hs00609452_g1, NM_199173.4.
4.6. ALP Staining, and Alizarin Red Staining
Cells were seeded under condition 2 for ALP and alizarin red staining. As for ALP staining,
the cells were stained at the prescribed date using the TRAP/ALP stain kit (Wako Pure Chemicals
Industries Ltd., Osaka, Japan). A quantitative ALP assay was performed using LabAssay ALP
(Wako Pure Chemicals Industries Ltd.). The ALP data were divided by the total quantity of DNA
evaluated with Quant-iT PicoGreen ds DNA Assay Kit (ThermoFisher Scientific Inc.). All assays
were performed in the accordance with manufacturer instructions.
Mineralization was assessed using alizarin red staining. In brief, the cells washed with
phosphate-buffered saline were fixed with 95% ethanol for 10 min. The cultures were stained
with alizarin red S (Sigma-Aldrich Co. LLC) for 30 min, followed by washing with distilled water
to remove the excess dye. A Canon A495 camera (Canon, Tokyo, Japan) was used to capture
images. As for the quantitative analysis of alizarin red staining, the stained wells were treated
with 10% formic acid. The mixture was shaken at the room temperature for 10 min to release the
dye. The absorbance of the supernatant was then evaluated with a SpectraMax M5 spectrometer
(Molecular Devices, Sunnyvale, CA, USA) at 415 nm.
4.7. Inhibitory Assay for Four Signaling Pathways
The cell signaling pathways associated with the osteogenic differentiation of the DFAT cells
induced by OM or OM(Dex) with EGCG were evaluated using four inhibitors—ERK1/2 (PD98059),
Akt (API-2), p38-MAPK (SB203580), and JNK (SP600125). These inhibitors were mixed with OM
+ EGCG(1.25) and OM(Dex) + EGCG(1.25) at the following concentrations: 1 µM for API-2; 2.5 and
25 µM for PD98059; 1 and 10 µM for SB203580; and 1 and 10 µM for SP600125. The cells were cultured
in the above-mentioned media under condition 2. At the prescribed date, the cells were stained with
alizarin red S and the quantitative data of the staining were used to determine the role of each signal
pathway. Relative inhibitory effect was calculated as follows: Inhibitory effect (%) = (absorbance of
sample/absorbance of benchmark) ˆ 100. Cells treated with OM or OM(Dex) with EGCG(1.25) were
used as the benchmark.
4.8. Statistical Analysis
Statistical significance was evaluated using a student’s t-test and one-way analysis of variance,
followed by a Tukey–Kramer test and Dunnett’s test. Microsoft Excel software statistical package was
used for the calculations. All experiments were performed with at least two independent replicates
and all of the results showed high reproducibility.
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5. Conclusions
In the present study, we provided evidence indicating that supplementation of an adequate
concentration of EGCG into osteogenic media is effective at inducing the proliferation, early
osteogenic differentiation, and mineralization of primary human DFAT cells. OM + EGCG induced
superior osteoblast differentiation in the cells than OM(Dex) + EGCG. These results indicate that
supplementation of EGCG into OM might be a prospective strategy to induce the osteoblastic
differentiation of DFAT cells that can be then used in bone regeneration therapy and drug screening.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/
1422-0067/16/12/26081/s1.
Acknowledgments: This study was partially supported by JSPS KAKENHI Grant Number 25861904. We
thank Naotaka Kishimoto (Department of Oral Anesthesiology, Osaka Dental University), Akihiro Nishio
(Department of Oral and Maxillofacial Surgery 2, Osaka Dental University), Takahiro Kashiwagi (Department
of Oral implantology, Osaka Dental University), and Hideaki Hori (Institute of Dental Research, Osaka Dental
University) for technical support.
Author Contributions: Yoshitomo Honda and Koji Kaida conceived and designed the experiments. Koji Kaida
performed and analyzed the experiments. Yoshitomo Honda and Koji Kaida drafted the manuscript. Yoshitomo
Honda, Yoshiya Hashimoto, Masahiro Tanaka and Shunsuke Baba thoroughly interpreted the data and revised
the manuscript for intellectual content. All authors discussed the results and commented on the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Egusa, H.; Sonoyama, W.; Nishimura, M.; Atsuta, I.; Akiyama, K. Stem cells in dentistry—Part I: Stem cell
sources. J. Prosthodont. Res. 2012, 56, 151–165. [CrossRef] [PubMed]
2. Lee, E.; Hui, J. The potential of stem cells in orthopaedic surgery. J. Bone Jt. Surg. 2006, 88B, 841–851.
[CrossRef] [PubMed]
3. Matsumoto, T.; Kano, K.; Kondo, D.; Fukuda, N.; Iribe, Y.; Tanaka, N.; Matsubara, Y.; Sakuma, T.;
Satomi, A.; Otaki, M.; et al. Mature adipocyte-derived dedifferentiated fat cells exhibit multilineage
potential. J. Cell. Physiol. 2008, 215, 210–222. [CrossRef] [PubMed]
4. Sugihara, H.; Yonemitsu, N.; Miyabara, S.; Yun, K. Primary cultures of unilocular fat cells: Characteristics
of growth in vitro and changes in differentiation properties. Differentiation 1986, 31, 42–49. [CrossRef]
[PubMed]
5. Huber, B.; Kluger, P.J. Decelerating mature adipocyte dedifferentiation by media composition. Tissue Eng.
Part C Methods 2015. [CrossRef] [PubMed]
6. Justesen, J.; Pedersen, S.B.; Stenderup, K.; Kassem, M. Subcutaneous adipocytes can differentiate into
bone-forming cells in vitro and in vivo. Tissue Eng. 2004, 10, 381–391. [CrossRef] [PubMed]
7. Kishimoto, N.; Momota, Y.; Hashimoto, Y.; Ando, K.; Omasa, T.; Kotani, J. Dedifferentiated fat cells
differentiate into osteoblasts in titanium fiber mesh. Cytotechnology 2013, 65, 15–22. [CrossRef] [PubMed]
8. Kishimoto, N.; Momota, Y.; Hashimoto, Y.; Tatsumi, S.; Ando, K.; Omasa, T.; Kotani, J. The osteoblastic
differentiation ability of human dedifferentiated fat cells is higher than that of adipose stem cells from the
buccal fat pad. Clin. Oral Investig. 2014, 18, 1893–1901. [CrossRef] [PubMed]
9. Kishimoto, N.; Momota, Y.; Mori, M.; Hashimoto, Y.; Imai, K.; Omasa, T.; Kotani, J. Bone regenration using
dedifferentiated fat cells with pure matrix. J. Oral Tissue Eng. 2008, 6, 127–134.
10. Kishimoto, N.; Momota, Y.; Hashimoto, Y.; Omasa, T.; Kotani, J. Self-assembling peptide RADA16 as a
scaffold in bone tissue engineering using dedifferentiated fat cells. J. Oral Tissue Eng. 2011, 8, 151–161.
11. Nakamura, T.; Shinohara, Y.; Momozaki, S.; Yoshimoto, T.; Noguchi, K. Co-stimulation with bone
morphogenetic protein-9 and FK506 induces remarkable osteoblastic differentiation in rat dedifferentiated
fat cells. Biochem. Biophys. Res. Commun. 2013, 440, 289–294. [CrossRef] [PubMed]
12. Shirakata, Y.; Nakamura, T.; Shinohara, Y.; Taniyama, K.; Sakoda, K.; Yoshimoto, T.; Noguchi, K. An
exploratory study on the efficacy of rat dedifferentiated fat cells (rDFATs) with a poly lactic-co-glycolic
acid/hydroxylapatite (PLGA/HA) composite for bone formation in a rat calvarial defect model. J. Mater.
Sci. Mater. Med. 2014, 25, 899–908. [CrossRef] [PubMed]
27997
Int. J. Mol. Sci. 2015, 16, 27988–28000
13. Oki, Y.; Watanabe, S.; Endo, T.; Kano, K. Mature adipocyte-derived dedifferentiated fat cells can
trans-differentiate into osteoblasts in vitro and in vivo only by all-trans retinoic acid. Cell Struct. Funct.
2008, 33, 211–222. [CrossRef] [PubMed]
14. Sakuma, T.; Matsumoto, T.; Kano, K.; Fukuda, N.; Obinata, D.; Yamaguchi, K.; Yoshida, T.; Takahashi, S.;
Mugishima, H. Mature, adipocyte derived, dedifferentiated fat cells can differentiate into smooth
muscle-like cells and contribute to bladder tissue regeneration. J. Urol. 2009, 182, 355–365. [CrossRef]
[PubMed]
15. Peng, X.; Song, T.; Hu, X.; Zhou, Y.; Wei, H.; Peng, J.; Jiang, S. Phenotypic and functional properties of
porcine dedifferentiated fat cells during the long-term culture in vitro. Biomed. Res. Int. 2015, 2015, 673651.
[CrossRef] [PubMed]
16. Okita, N.; Honda, Y.; Kishimoto, N.; Liao, W.; Azumi, E.; Hashimoto, Y.; Matsumoto, N. Supplementation
of strontium to a chondrogenic medium promotes chondrogenic differentiation of human dedifferentiated
fat cells. Tissue Eng. Part A 2015, 21, 1695–1704. [CrossRef] [PubMed]
17. Yagi, K.; Kondo, D.; Okazaki, Y.; Kano, K. A novel preadipocyte cell line established from mouse adult
mature adipocytes. Biochem. Biophys. Res. Commun. 2004, 321, 967–974. [CrossRef] [PubMed]
18. Kazama, T.; Fujie, M.; Endo, T.; Kano, K. Mature adipocyte-derived dedifferentiated fat cells can
transdifferentiate into skeletal myocytes in vitro. Biochem. Biophys. Res. Commun. 2008, 377, 780–785.
[CrossRef] [PubMed]
19. Jumabay, M.; Matsumoto, T.; Yokoyama, S.; Kano, K.; Kusumi, Y.; Masuko, T.; Mitsumata, M.; Saito, S.;
Hirayama, A.; Mugishima, H.; et al. Dedifferentiated fat cells convert to cardiomyocyte phenotype and
repair infarcted cardiac tissue in rats. J. Mol. Cell. Cardiol. 2009, 47, 565–575. [CrossRef] [PubMed]
20. Obinata, D.; Matsumoto, T.; Ikado, Y.; Sakuma, T.; Kano, K.; Fukuda, N.; Yamaguchi, K.; Mugishima, H.;
Takahashi, S. Transplantation of mature adipocyte-derived dedifferentiated fat (DFAT) cells improves
urethral sphincter contractility in a rat model. Int. J. Urol. 2011, 18, 827–834. [CrossRef] [PubMed]
21. Jumabay, M.; Abdmaulen, R.; Urs, S.; Heydarkhan-Hagvall, S.; Chazenbalk, G.D.; Jordan, M.C.; Roos, K.P.;
Yao, Y.; Bostrom, K.I. Endothelial differentiation in multipotent cells derived from mouse and human white
mature adipocytes. J. Mol. Cell. Cardiol. 2012, 53, 790–800. [CrossRef] [PubMed]
22. Shen, J.F.; Sugawara, A.; Yamashita, J.; Ogura, H.; Sato, S. Dedifferentiated fat cells: An alternative source
of adult multipotent cells from the adipose tissues. Int. J. Oral Sci. 2011, 3, 117–124. [CrossRef] [PubMed]
23. Watson, J.E.; Patel, N.A.; Carter, G.; Moor, A.; Patel, R.; Ghansah, T.; Mathur, A.; Murr, M.M.; Bickford, P.;
Gould, L.J.; et al. Comparison of markers and functional attributes of human adipose-derived stem cells
and dedifferentiated adipocyte cells from subcutaneous fat of an obese diabetic donor. Adv. Wound Care
2014, 3, 219–228. [CrossRef] [PubMed]
24. Sakamoto, F.; Hashimoto, Y.; Kishimoto, N.; Honda, Y.; Matsumoto, N. The utility of human
dedifferentiated fat cells in bone tissue engineering in vitro. Cytotechnology 2013, 67, 75–84. [CrossRef]
[PubMed]
25. Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises?
Int. J. Mol. Sci. 2011, 12, 5592–5603. [CrossRef] [PubMed]
26. Chung, J.H.; Han, J.H.; Hwang, E.J.; Seo, J.Y.; Cho, K.H.; Kim, K.H.; Youn, J.I.; Eun, H.C. Dual mechanisms
of green tea extract (EGCG)-induced cell survival in human epidermal keratinocytes. FASEB J. 2003, 17,
1913–1915. [PubMed]
27. Park, G.; Yoon, B.S.; Moon, J.H.; Kim, B.; Jun, E.K.; Oh, S.; Kim, H.; Song, H.J.; Noh, J.Y.; Oh, C.; et al.
Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid
fibroblasts via inhibition of the STAT3-signaling pathway. J. Investig. Dermatol. 2008, 128, 2429–2441.
[CrossRef] [PubMed]
28. Takai, S.; Matsushima-Nishiwaki, R.; Adachi, S.; Natsume, H.; Minamitani, C.; Mizutani, J.; Otsuka, T.;
Tokuda, H.; Kozawa, O. (´)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated
interleukin-6 synthesis in osteoblasts: Suppression of SAPK/JNK. Med. Inflamm. 2008, 2008, 291808.
[CrossRef] [PubMed]
29. Wang, Y.; Ren, X.; Deng, C.; Yang, L.; Yan, E.; Guo, T.; Li, Y.; Xu, M.X. Mechanism of the inhibition of the
STAT3 signaling pathway by EGCG. Oncol. Rep. 2013, 30, 2691–2696. [PubMed]
27998
Int. J. Mol. Sci. 2015, 16, 27988–28000
30. Masuda, M.; Suzui, M.; Lim, J.T.; Deguchi, A.; Soh, J.W.; Weinstein, I.B. Epigallocatechin-3-gallate decreases
VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of
signal transduction. J. Exp. Ther. Oncol. 2002, 2, 350–359. [CrossRef] [PubMed]
31. Kim, H.; Sakamoto, K. (´)-Epigallocatechin gallate suppresses adipocyte differentiation through the
MEK/ERK and PI3K/Akt pathways. Cell Biol. Int. 2012, 36, 147–153. [CrossRef] [PubMed]
32. Jin, P.; Wu, H.; Xu, G.; Zheng, L.; Zhao, J. Epigallocatechin-3-gallate (EGCG) as a pro-osteogenic agent to
enhance osteogenic differentiation of mesenchymal stem cells from human bone marrow: An in vitro study.
Cell Tissue Res. 2014, 356, 381–390. [CrossRef] [PubMed]
33. Vali, B.; Rao, L.G.; El-Sohemy, A. Epigallocatechin-3-gallate increases the formation of mineralized bone
nodules by human osteoblast-like cells. J. Nutr. Biochem. 2007, 18, 341–347. [CrossRef] [PubMed]
34. Ikeda, I. Multifunctional effects of green tea catechins on prevention of the metabolic syndrome. Asia Pac.
J. Clin. Nutr. 2008, 17 (Suppl. S1), 273–274. [PubMed]
35. Venkateswara, B.; Sirisha, K.; Chava, V. Green tea extract for periodontal health. J. Indian Soc. Periodontol.
2011, 15, 18–22. [CrossRef] [PubMed]
36. Maeda, K.; Kuzuya, M.; Cheng, X.W.; Asai, T.; Kanda, S.; Tamaya-Mori, N.; Sasaki, T.; Shibata, T.;
Iguchi, A. Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement
barrier. Atherosclerosis 2003, 166, 23–30. [CrossRef]
37. Rodriguez, R.; Kondo, H.; Nyan, M.; Hao, J.; Miyahara, T.; Ohya, K.; Kasugai, S. Implantation of green tea
catechin α-tricalcium phosphate combination enhances bone repair in rat skull defects. J. Biomed. Mater.
Res. B Appl. Biomater. 2011, 98, 263–271. [CrossRef] [PubMed]
38. Shen, B.; Wei, A.; Tao, H.; Diwan, A.D.; Ma, D.D. BMP-2 enhances TGF-β3-mediated chondrogenic
differentiation of human bone marrow multipotent mesenchymal stromal cells in alginate bead culture.
Tissue Eng. Part A 2009, 15, 1311–1320. [CrossRef] [PubMed]
39. Honda, Y.; Tanaka, T.; Tokuda, T.; Kashiwagi, T.; Kaida, K.; Hieda, A.; Umezaki, Y.; Hashimoto, Y.; Imai, K.;
Matsumoto, N.; et al. Local controlled release of polyphenol conjugated with gelatin facilitates bone
formation. Int. J. Mol. Sci. 2015, 16, 14143–14157. [CrossRef] [PubMed]
40. Shen, C.L.; Yeh, J.K.; Cao, J.J.; Wang, J.S. Green tea and bone metabolism. Nutr. Res. 2009, 29, 437–456.
[CrossRef] [PubMed]
41. Kanzaki, H.; Shinohara, F.; Itohiya-Kasuya, K.; Ishikawa, M.; Nakamura, Y. Nrf2 Activation attenuates both
orthodontic tooth movement and relapse. J. Dent. Res. 2015, 94, 787–794. [CrossRef] [PubMed]
42. Chen, C.H.; Ho, M.L.; Chang, J.K.; Hung, S.H.; Wang, G.J. Green tea catechin enhances osteogenesis in a
bone marrow mesenchymal stem cell line. Osteoporos. Int. 2005, 16, 2039–2045. [CrossRef] [PubMed]
43. Wei, Y.J.; Tsai, K.S.; Lin, L.C.; Lee, Y.T.; Chi, C.W.; Chang, M.C.; Tsai, T.H.; Hung, S.C. Catechin stimulates
osteogenesis by enhancing PP2A activity in human mesenchymal stem cells. Osteoporos. Int. 2011, 22,
1469–1479. [CrossRef] [PubMed]
44. Kamon, M.; Zhao, R.; Sakamoto, K. Green tea polyphenol (´)-epigallocatechin gallate suppressed the
differentiation of murine osteoblastic MC3T3-E1 cells. Cell Biol. Int. 2009, 34, 109–116. [PubMed]
45. Strohbach, C.; Strong, D.; Rundle, C. Gene Therapy Applications for Fracture Repair. In Gene Therapy
Applications; Kang, C., Ed.; INTECH: Rijeka, Croatia, 2011; pp. 201–226.
46. Golub, E.; Boesze-Battaglia, K. The role of alkaline phosphatase in mineralization. Curr. Opin. Orthop. 2007,
18, 444–448. [CrossRef]
47. Mikami, Y.; Asano, M.; Honda, M.J.; Takagi, M. Bone morphogenetic protein 2 and dexamethasone
synergistically increase alkaline phosphatase levels through JAK/STAT signaling in C3H10T1/2 cells.
J. Cell. Physiol. 2010, 223, 123–133. [CrossRef] [PubMed]
48. Harmey, D.; Hessle, L.; Narisawa, S.; Johnson, K.A.; Terkeltaub, R.; Millan, J.L. Concerted regulation
of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank: An integrated model of the
pathogenesis of mineralization disorders. Am. J. Pathol. 2004, 164, 1199–1209. [CrossRef]
49. Peruzzi, B.; Cappariello, A.; del Fattore, A.; Rucci, N.; de Benedetti, F.; Teti, A. c-Src and IL-6 inhibit
osteoblast differentiation and integrate IGFBP5 signalling. Nat. Commun. 2012, 3, 630. [CrossRef] [PubMed]
50. Chipoy, C.; Berreur, M.; Couillaud, S.; Pradal, G.; Vallette, F.; Colombeix, C.; Redini, F.; Heymann, D.;
Blanchard, F. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by
oncostatin M in osteosarcoma cells require PKCδ and STAT3. J. Bone Miner. Res. 2004, 19, 1850–1861.
[CrossRef] [PubMed]
27999
Int. J. Mol. Sci. 2015, 16, 27988–28000
51. Nicolaidou, V.; Wong, M.M.; Redpath, A.N.; Ersek, A.; Baban, D.F.; Williams, L.M.; Cope, A.P.;
Horwood, N.J. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote
osteoblast formation. PLoS ONE 2012, 7, e39871. [CrossRef] [PubMed]
52. Langenbach, F.; Handschel, J. Effects of dexamethasone, ascorbic acid and β-glycerophosphate on the
osteogenic differentiation of stem cells in vitro. Stem Cell Res. Ther. 2013, 4, 117. [CrossRef] [PubMed]
53. Zuk, P.A.; Zhu, M.; Mizuno, H.; Huang, J.; Futrell, J.W.; Katz, A.J.; Benhaim, P.; Lorenz, H.P.; Hedrick, M.H.
Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng. 2001, 7,
211–228. [CrossRef] [PubMed]
54. Hattori, H.; Masuoka, K.; Sato, M.; Ishihara, M.; Asazuma, T.; Takase, B.; Kikuchi, M.; Nemoto, K. Bone
formation using human adipose tissue-derived stromal cells and a biodegradable scaffold. J. Biomed. Mater.
Res. B Appl. Biomater. 2006, 76, 230–239. [CrossRef] [PubMed]
55. Song, I.H.; Caplan, A.I.; Dennis, J.E. In vitro dexamethasone pretreatment enhances bone formation of
human mesenchymal stem cells in vivo. J. Orthop. Res. 2009, 27, 916–921. [CrossRef] [PubMed]
56. Honda, Y.; Ding, X.; Mussano, F.; Wiberg, A.; Ho, C.M.; Nishimura, I. Guiding the osteogenic fate of mouse
and human mesenchymal stem cells through feedback system control. Sci. Rep. 2013, 3, 3420. [CrossRef]
[PubMed]
57. Bertolo, A.; Schlaefli, P.; Malonzo-marty, C.; Baur, M.; Potzel, T.; Steffen, F.; Stoyanov, J. Comparative
characterization of canine and human mesenchymal stem cells derived from bone marrow. Int. J. Stem
Cell Res. Ther. 2015, 2, 1–6.
58. Hamidouche, Z.; Hay, E.; Vaudin, P.; Charbord, P.; Schule, R.; Marie, P.J.; Fromigue, O. FHL2 mediates
dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/β-catenin
signaling-dependent Runx2 expression. FASEB J. 2008, 22, 3813–3822. [CrossRef] [PubMed]
59. Fey, D.; Croucher, D.R.; Kolch, W.; Kholodenko, B.N. Crosstalk and signaling switches in mitogen-activated
protein kinase cascades. Front. Physiol. 2012, 3, 355. [CrossRef] [PubMed]
60. Manning, B.D.; Cantley, L.C. AKT/PKB signaling: Navigating downstream. Cell 2007, 129, 1261–1274.
[CrossRef] [PubMed]
61. Arzate-Mejia, R.G.; Valle-Garcia, D.; Recillas-Targa, F. Signaling epigenetics: Novel insights on cell
signaling and epigenetic regulation. IUBMB Life 2011, 63, 881–895. [CrossRef] [PubMed]
62. Nauth, A.; Schemitsch, E.H. Stem cells for the repair and regeneration of bone. Indian J. Orthop. 2012, 46,
19–21. [PubMed]
63. Kikuta, S.; Tanaka, N.; Kazama, T.; Kazama, M.; Kano, K.; Ryu, J.; Tokuhashi, Y.; Matsumoto, T. Osteogenic
effects of dedifferentiated fat cell transplantation in rabbit models of bone defect and ovariectomy-induced
osteoporosis. Tissue Eng. Part A 2013, 19, 1792–1802. [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open
access article distributed under the terms and conditions of the Creative Commons by
Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
28000
